Three multicenter prospective studies have treated more than 1,500 patients. Patients show nearly a 30% reduction in IOP at 1 year with minimal safety concerns. The device is available in the EU.
“The eyes are typically quiet after treatment,” said CEO Dietrich Wolf, PhD. “We never saw any major adverse events and visual acuity stays as it was before treatment.”